The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-cell RNA and T cell receptor (TCR) sequencing in patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) after induction CTLA4 and PD-1 immune checkpoint blockade (ICB).
 
Xianli Jiang
Patents, Royalties, Other Intellectual Property - Intellectual property application filed on August 2022 for Invention entitled: 'METHODS FOR ROBUST DESIGN OF MODULAR REPRESSORS'
 
Nils-Petter Rudqvist
No Relationships to Disclose
 
Shaoheng Liang
Employment - NuProbe
Consulting or Advisory Role - Torus Biosystems
 
Shengbin Ye
No Relationships to Disclose
 
Shan He
No Relationships to Disclose
 
Qingnan Liang
No Relationships to Disclose
 
Michael A. Curran
Leadership - ImmunoGenesis
Stock and Other Ownership Interests - Agenus (I); ImmunoGenesis; ImmunOs Therapeutics; Sana Biotechnology (I)
Consulting or Advisory Role - Adagene; Agenus; Alligator Bioscience; Amunix; Aptevo Therapeutics; AstraZeneca/MedImmune; ImmunOs Therapeutics; Nurix; OncoResponse; Tentarix Biotherapeutics; Xencor
Research Funding - ImmunoGenesis
Patents, Royalties, Other Intellectual Property - The Regents of the University of California, James Allison and Michael Curran. Methods and Composition for Localized Secretion of Anti-CTLA-4 Antibodies, United States, US 9,868,961 B2.; The University of Texas MD Anderson Cancer Center, Philip Jones, Maria Emilia DiFrancesco, Michael A. Curran. Cyclic Dinucleotides as Agonists of Stimulator of Interferon Gene Dependent Signaling, United States, 62/461,642.; The University of Texas, MD Anderson Cancer Center, Michael A. Curran, Carlo Toniatti, Ashvin R. Jaiswal, Dongxing Zha, and Voo Kui. Dual specificity antibodies which bind both PD-L1 and PD-L2 and prevent their binding to PD-1, United States, PCT/US2019/0
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; ImmunOs Therapeutics
 
Bo Jiang
No Relationships to Disclose
 
Jagannadha Sastry
Consulting or Advisory Role - Phoenix Biotech
 
Keiko Akagi
No Relationships to Disclose
 
Michelle D. Williams
Consulting or Advisory Role - Bayer Health
Speakers' Bureau - Bayer
 
Jack Phan
No Relationships to Disclose
 
Neil D. Gross
Honoraria - Intuitive Surgical
Consulting or Advisory Role - Dragonfly Therapeutics; Genzyme; PDS Biotechnology; Sanofi/Regeneron; Shattuck Labs; Verb Surgical (Inst)
Research Funding - Genentech (Inst); MedImmune (Inst); Regeneron
Patents, Royalties, Other Intellectual Property - UpToDate
 
Meng Li
Stock and Other Ownership Interests - Canary Analytics
Patents, Royalties, Other Intellectual Property - Intellectual property disclosure submitted to Rice for patent filing. Invention title:
 
Ken Chen
No Relationships to Disclose
 
Maura L. Gillison
Consulting or Advisory Role - Bayer; Bicara Therapeutics; BioNTech; BioNTech; Bristol-Myers Squibb; Caladrius Biosciences; Coherus Biosciences; Debiopharm Group; Eisai; EMD Serono; Exelixis; Gilead Sciences; Ipsen; Istari; ITeos Therapeutics; Kura Oncology; LLX Solutions; Merck; Mirati Therapeutics; Nektar; OncLive; Seagen; Sensei Biotherapeutics; Shattuck Labs
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genentech (Inst); Genocea Biosciences (Inst); Kura Oncology (Inst); Seagen (Inst)